2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS

FINAL
November 29, 2017

Working Group: Joanne Langley (Chair), Marie-Astrid Lefebvre, John Conly, Joanne Embree, Bonita Lee, Jeannette Comeau, Patricia Bedard (IPAC), K. Amaratunga (PHAC) and Robyn Mitchell (PHAC)

Contact:

Public Health Agency of Canada
CNISP Surveillance Officer
Fax: 613-946-0678
E-mail: cnisp.pcsin@phac-aspc.gc.ca
Mail: Public Health Agency of Canada
130 Colonnade Road, PL6504B
Ottawa, ON K1A 0K9
I. OBJECTIVES

1. To determine the incidence of cerebrospinal fluid (CSF) shunt infections in patients of all ages admitted to Canadian hospitals participating in the CNISP.
2. To describe the microbiology and epidemiology of CSF shunt infections in all patients with:
   a. New shunts and/or;
   b. Revisions to an existing internalized shunt.

II. METHODOLOGY

A. Surveillance design

Ongoing, prospective surveillance for infections following placement of an internalized CSF shunt or revision or other surgical manipulation of an existing shunt.

B. Inclusion & exclusion criteria

Eligible CNISP hospitals are those able to perform year-round surveillance for CSF shunt-associated infections, and are able to document the number of surgical placements and revisions of shunts.

Patient inclusion criteria

- Person of any age admitted to a CNISP hospital that undergoes placement or revision of a CSF shunting device.
- Infection occurs within one year of surgery.

Patient exclusion criteria:

- Patients with transcutaneous or external shunting devices or non-shunting devices (e.g. Ommaya reservoir).
- Patients whose CSF was culture positive (bacterial or fungal) at the time of placement of the shunt.
- Infections in which the device associated with the positive organism was not placed at the hospital where the infection was identified, i.e. the hospital should not report the infection.

C. Surveillance period

Infections that develop within 12 months of the shunt procedure will be included.
D. Numerator data

A CSF shunt infection is defined as:

An internalized CSF shunting device is in place AND a bacterial or fungal pathogen(s) is identified from the cerebrospinal fluid AND is associated with at least ONE of the following:

a) fever (temperature ≥38º C),

OR

b) neurological signs or symptoms,

OR

c) abdominal signs or symptoms,

OR

d) signs or symptoms of shunt malfunction or obstruction

The date of the infection is assigned to the date of procedure.

Relapse vs. new infection

Re-infection of a shunt is defined as an infectious episode occurring after diagnosis of a CSF shunt infection and/or completion of antibiotic therapy, with a CSF bacterial or fungal isolate different from the previous infection. Such a patient would be eligible to be counted as a new CSF shunt-associated infection.

Relapse of a shunt infection is an infectious episode occurring within 1 month of completion of therapy with an isolate of the same genus. This event is NOT eligible to be counted as a new CSF shunt-associated infection.

E. Denominator data

The denominator for the shunt infection rate is the number of shunt surgeries at the site.

Each participating facility will submit (Appendix C):

- The number of surgical placements for new CSF shunts for pediatric (< 18 years) and adult (≥ 18 years) cases.
- The number of surgical revisions to existing CSF shunts for pediatric (< 18 years) and adult (≥ 18 years) cases.

F. Data collection and reporting

Patients with a CSF shunt-associated infection will be identified through review of positive CSF organisms from the microbiology laboratory. Once a positive organism is identified, a chart (health record) review will be conducted to determine if the device associated with that organism was placed at the hospital where the infection was identified and that the surgery occurred in the previous 12 months.

Each time an infection is identified a patient questionnaire (Appendix A) will be completed. All completed forms will be emailed to CNISP at the email address below. Please keep copies for your records. If it is not possible to email data, please submit by fax or hard copy mail and notify CNISP by email that the forms have been sent by this route.
Please submit data to:
E-mail: cnisp.pcsin@phac-aspc.gc.ca

Public Health Agency of Canada
CNISP Surveillance Officer
Fax: 613-946-0678
Mail: Public Health Agency of Canada
130 Colonnade Road, PL6504B
Ottawa, ON K1A 0K9
Appendix A – 2018 CSF shunt patient questionnaire

1. CHEC Site: _____________________
2. Unique Patient ID: _____________________
   *(CHEC site #) (year) (case number)*

3. Date of birth ______/_____/_______
   OR Age ___________
   *(dd/mmm/yyyy) □ Years □ Months □ Days*

4. Gender □ Male □ Female

5. Pathogen(s) isolated from CSF (please check all that apply):
   □ *Alpha hemolytic Streptococcus*
   □ *Propionibacterium species*
   □ *Coagulase negative Staphylococcus spp*
   □ *Haemophilus influenza type B*
   □ *Escherichia coli*
   □ *Staphylococcus aureus*
   □ *Corynebacterium species*
   □ *Pseudomonas aeruginosa*
   □ Other, please specify: _____________________
   □ MSSA □ MRSA

6a. Method of identification □ Culture □ Molecular method – see 6b.

6b. Please specify the type of molecular method: ________________________________

7. Date of CSF shunt procedure ______/_____/_______
   *(dd/mmm/yyyy)*

8. Date organism was obtained from CSF ______/_____/_______
   *(dd/mmm/yyyy)*

9. The shunt surgery was: (please check one the following):
   □ revision of an existing internal shunt
   □ placement of entirely new shunt

10. Type of CSF shunt inserted was: (please check one the following):
    □ VP (ventriculoperitoneal) □ LP (lumbo-peritoneal)
    □ VA (ventriculoatrial) □ Other (please specify): ________________________________
11. Please indicate the organism(s) AND their susceptibility/resistance for any of the following antimicrobials/antifungals listed below: (R for resistant, S for susceptible, I for intermediate)

<table>
<thead>
<tr>
<th>Please specify the organism:</th>
<th>Organism 1:</th>
<th>Organism 2:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Amoxicillin-clavulanic acid</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Caspofungin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cefazolin (Ancef)</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cephalexin (Keflex)</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cefepime</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Cloxacillin / Oxacillin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Ertapenem</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Imipenem</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Linezolid</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Meropenem</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Micafungin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Moxifloxacin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Penicillin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Piperacillin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Rifampin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Ticarcillin-clavulanic acid</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Trimetoprim-sulfamethoxazole</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
<tr>
<td>Other, specify:</td>
<td>□ R □ I □ S</td>
<td>□ R □ I □ S</td>
</tr>
</tbody>
</table>
Appendix B - Instructions on Completing Patient Questionnaire (Appendix A)

Q1. CHEC site

This will be the 3-character alphanumeric number assigned to your institution. It will always begin with the two digit number assigned to your CHEC member e.g., 07, 15, and a letter assigned by the CHEC member for that specific institution e.g., A, B, C, etc. The CHEC Site # for each institution should always be the same for all the CHEC/CNISP surveillance projects and will always have all three alphanumeric digits reported as the CHEC Site #, e.g., 07A, 15A.

Q2. Unique patient identifier

This number should never be longer than 8 characters. The 8 characters should consist of the 3 character CHEC site # (e.g., 09A), the surveillance year (e.g., 18), and a consecutive number starting at 001 and continuing on with each additional case. An example of the first case in an Institution would be 09A18001. An example of the thirty-fifth case would be 09A18035, and so on. Use the same number with a lower case letter at the end if >1 SSI occurs following the same surgery (e.g., 07A18001a).

Note: Please do not include dashes as separators in between the sets of characters

Q3. Date of birth (DOB)

Please enter Day (##), Month (May) and Year (1947) in this order. If the date of birth is not available please enter the patient’s age (in years, months or days).

Q4. Gender

Check male or female gender as appropriate.

Q5. Pathogen(s) isolated

Please list all microorganisms isolated from the CSF as reported by the laboratory. If ‘other’ pathogen is checked, please specify the organism in the text field.

Note: MSSA = methicillin sensitive Staphylococcus aureus and MRSA = methicillin resistant Staphylococcus aureus.

Q6a. Method of identification

Please indicate if the organism was identified by culture or a molecular method.
Q6b. Molecular method

If identified by molecular method, please indicate the method used (e.g. PCR).

Q7. Date of CSF shunt procedure

Please enter Day (##), Month (May) and Year (2018) in this order.

Q8. Date positive CSF organism was obtained

Please enter the date the positive CSF organism was obtained Day (##), Month (May) and Year (2018).

Q9. Type of shunt surgery

Please indicate whether the surgery was for the revision of an existing internal shunt or the placement of an entirely new shunt. If an existing shunt is completely removed and a new device is placed at the same time, please check placement of a new shunt. Please check only ONE box.

Q10. Type of CSF shunt inserted

Please indicate the type of CSF shunt system inserted (i.e. ventriculoperitoneal, ventriculoatrial, lumbo-peritoneal shunt or other). If other, please specify in the text field.

Q11. Antibiogram results

Please indicate the organism(s) AND their susceptibility/resistance to the antibiotics tested (S = Susceptible, I = Intermediate or R = Resistant).
Appendix C – 2018 CSF shunt denominator form

CHEC #: ____________________________

Surveillance period: January 1, 2018 to December 31, 2018

Please provide the following number of surgical placements for the surveillance period year:

<table>
<thead>
<tr>
<th></th>
<th>&lt; 18 years of age</th>
<th>&gt; 18 years of age</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of surgical placements of new CSF shunts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of surgical revisions to existing CSF shunts placements</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For 2018, were there zero (0) cases reported for your site?  □ Yes  □ No

**Please send your completed form by March 31, 2019 by e-mail to:**

**Public Health Agency of Canada**
CNISP Surveillance Officer
Fax: 613-946-0678
E-mail: cnisp.pcsin@phac-aspc.gc.ca
Mail: Public Health Agency of Canada
130 Colonnade Road, PL6504B
Ottawa, ON K1A 0K9
Appendix D – CNISP CSF shunt-associated infection record

**Note:** This is a resource/tool for sites to assist with record keeping. It is not a requirement for sites to use this table. Please feel free to modify as needed. Please do **NOT** send to CNISP.

<table>
<thead>
<tr>
<th>Patient unique identifier</th>
<th>Gender (M/F)</th>
<th>Date of Birth (DD/MM/YYYY)</th>
<th>Procedure Date (DD/MM/YYYY)</th>
<th>Date positive organism (DD/MM/YYYY)</th>
<th>Date patient questionnaire sent to CNISP</th>
<th>Recorder initials</th>
</tr>
</thead>
<tbody>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>...18................. CHEC# case#</td>
<td>□ Male □ Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Revision history

November 2017 - Question regarding method of identification (e.g. culture or molecular) was added
  - Option to indicate zero cases reported on denominator form
  - Included a tool to assist sites with record keeping (Appendix D)